Home » Stocks » APLT

Applied Therapeutics, Inc. (APLT)

Stock Price: $14.20 USD -1.67 (-10.52%)
Updated May 13, 2021 3:59 PM EDT - Market closed
After-hours: $14.16 -0.04 (-0.28%) May 13, 4:00 PM
Market Cap 427.21M
Revenue (ttm) n/a
Net Income (ttm) -105.77M
Shares Out 24.14M
EPS (ttm) -4.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $14.20
Previous Close $15.87
Change ($) -1.67
Change (%) -10.52%
Day's Open 16.10
Day's Range 13.94 - 16.59
Day's Volume 208,529
52-Week Range 13.58 - 51.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency

2 days ago - GlobeNewsWire

AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA

1 month ago - GlobeNewsWire

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

2 months ago - GlobeNewsWire

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against v...

2 months ago - GlobeNewsWire

Applied Therapeutics Inc (NASDAQ: APLT) prices its underwritten public offering of 3 million at $23 per share, raising $69 million in gross proceeds, at a marginal premium of 2%. Underwriters have an op...

3 months ago - Benzinga

NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against v...

3 months ago - GlobeNewsWire

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against v...

3 months ago - GlobeNewsWire

FDA Clinical Hold Lifted

3 months ago - GlobeNewsWire

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

5 months ago - GlobeNewsWire

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

5 months ago - GlobeNewsWire

Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics)

6 months ago - GlobeNewsWire

Treatment with AT-001 normalizes cardiac energetics and improves cardiac function in a mouse model of Diabetic Cardiomyopathy (DbCM) Treatment with AT-001 normalizes cardiac energetics and improves card...

6 months ago - GlobeNewsWire

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

6 months ago - GlobeNewsWire

Applied Therapeutics Inc. (APLT) closed at $22.86 in the latest trading session, marking a -0.95% move from the prior day.

7 months ago - Zacks Investment Research

Applied Therapeutics Inc. (NASDAQ: APLT) shares pushed higher on Thursday after a new analyst report came out supposing massive upside for this biotech.

7 months ago - 24/7 Wall Street

Applied Therapeutics Inc. (APLT) closed at $20.02 in the latest trading session, marking a +0.05% move from the prior day.

7 months ago - Zacks Investment Research

NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated mole...

7 months ago - GlobeNewsWire

NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated mole...

7 months ago - GlobeNewsWire

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated mole...

8 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $APLT #fraud--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Investors

8 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $APLT #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Applied Therapeutics, Inc.

8 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $APLT #APLT--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc.

8 months ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $APLT #fraud--INVESTOR ALERT: Law Offices of Howard G.

8 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $APLT #APLT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc.

8 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. (NASDAQ: A...

8 months ago - Business Wire

NEW YORK, Aug. 18, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc.

8 months ago - PRNewsWire

NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molec...

9 months ago - GlobeNewsWire

In the latest trading session, Applied Therapeutics Inc. (APLT) closed at $25.93, marking a +0.5% move from the previous day.

9 months ago - Zacks Investment Research

Applied Therapeutics Inc. (APLT) closed the most recent trading day at $25.74, moving +1.74% from the previous trading session.

9 months ago - Zacks Investment Research

During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.

9 months ago - Zacks Investment Research

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: FREQ, GRBK, KELYA
9 months ago - Zacks Investment Research

NEW YORK, July 17, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molec...

9 months ago - GlobeNewsWire

Is (APLT) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

On July 1, 2020, a fraudulent “short report” was posted.

10 months ago - GlobeNewsWire

Applied Therapeutics (APLT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

Applied Therapeutics Inc. (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

10 months ago - Zacks Investment Research

AT-007 pediatric Galactosemia study (ACTION-Galactosemia Kids) initiated

10 months ago - GlobeNewsWire

NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molec...

11 months ago - GlobeNewsWire

NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecu...

11 months ago - GlobeNewsWire

NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecu...

1 year ago - GlobeNewsWire

New AT-001 IND opened with FDA for acute lung inflammation and cardiomyopathy in critical COVID-19 patients

1 year ago - GlobeNewsWire

Applied Therapeutics: This Is A Good Entry Point

1 year ago - Seeking Alpha

NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical...

1 year ago - GlobeNewsWire

Better-than-expected earnings, positive development in the U.S.-China trade relationship, China stimulus measures, easing policies and slew of upbeat economic data buoyed the stocks.

Other stocks mentioned: CYH, ENPH, FLGT, TNDM
1 year ago - Zacks Investment Research

The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.

Other stocks mentioned: ABEO, EBF, ONTX, PTI
1 year ago - Zacks Investment Research

These three clinical-stage biotechs could all double in value before year's end.

Other stocks mentioned: ADAP, KNSA
1 year ago - The Motley Fool

While the record rally in Tesla stock has garnered all the attention over the past six months, these growth stocks have been just as hot.

Other stocks mentioned: CDLX, EVER, FCEL, HOV, HOVNP
1 year ago - InvestorPlace

NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against...

1 year ago - GlobeNewsWire

NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against...

1 year ago - GlobeNewsWire

NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against...

1 year ago - GlobeNewsWire

About APLT

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III ... [Read more...]

Industry
Biotechnology
IPO Date
May 14, 2019
Stock Exchange
NASDAQ
Ticker Symbol
APLT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for APLT stock is "Strong Buy." The 12-month stock price forecast is 48.50, which is an increase of 241.55% from the latest price.

Price Target
$48.50
(241.55% upside)
Analyst Consensus: Strong Buy